TP53 Mutations and TET2 Deficiency Cooperate to Drive Leukemogenesis and Establish an Immunosuppressive Environment

In mice, combined hematopoietic-specific deletion of TET2 and TP53 resulted in enhanced self-renewal compared to deletion of either gene alone. Tp53/Tet2 double knockout mice developed serially transplantable AML.